{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:03:16Z","timestamp":1790110996922,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08083-4","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:08:42Z","timestamp":1790107722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5003-7907","authenticated-orcid":false,"given":"Phi Y.","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8878-958X","authenticated-orcid":false,"given":"Binh V.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1869-641X","authenticated-orcid":false,"given":"Vinh T.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-814X","authenticated-orcid":false,"given":"Tu T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"8083_CR1","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1200\/jco.2006.07.2793","volume":"24","author":"JM Walshe","year":"2006","unstructured":"Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769\u20135779. https:\/\/doi.org\/10.1200\/jco.2006.07.2793","journal-title":"J Clin Oncol"},{"key":"8083_CR2","doi-asserted-by":"publisher","first-page":"e2343910","DOI":"10.1001\/jamanetworkopen.2023.43910","volume":"6","author":"R Kabirian","year":"2023","unstructured":"Kabirian R et al (2023) Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer. JAMA Netw Open 6:e2343910. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.43910","journal-title":"JAMA Netw Open"},{"key":"8083_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdh266","volume":"15","author":"S Di Cosimo","year":"2004","unstructured":"Di Cosimo S et al (2004) Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 15:1065\u20131071. https:\/\/doi.org\/10.1093\/annonc\/mdh266","journal-title":"Ann Oncol"},{"key":"8083_CR4","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M et al (2020) Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 31:1664\u20131678. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.006","journal-title":"Ann Oncol"},{"key":"8083_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jnci\/djr541","volume":"104","author":"J Howard-Anderson","year":"2012","unstructured":"Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104:386\u2013405. https:\/\/doi.org\/10.1093\/jnci\/djr541","journal-title":"J Natl Cancer Inst"},{"key":"8083_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/op-24-00634","volume":"21","author":"L Arecco","year":"2025","unstructured":"Arecco L et al (2025) The value of offering oncofertility counseling in young patients with newly diagnosed cancer is unquestionable. JCO Oncol Pract 21:578\u2013579. https:\/\/doi.org\/10.1200\/op-24-00634","journal-title":"JCO Oncol Pract"},{"key":"8083_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107\u2013118. https:\/\/doi.org\/10.1056\/NEJMoa1404037","journal-title":"N Engl J Med"},{"key":"8083_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA et al (2018) Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379:122\u2013137. https:\/\/doi.org\/10.1056\/NEJMoa1803164","journal-title":"N Engl J Med"},{"key":"8083_CR9","doi-asserted-by":"publisher","unstructured":"Pistilli B, Lohrisch C, Sheade J, Fleming GF (2022) Personalizing adjuvant endocrine therapy for early-stage hormone receptor\u2013positive breast cancer. Am Soc Clin Oncol Educ Book 60\u201372. https:\/\/doi.org\/10.1200\/edbk_350358","DOI":"10.1200\/edbk_350358"},{"key":"8083_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2407-8-56","volume":"8","author":"M Berliere","year":"2008","unstructured":"Berliere M et al (2008) Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8:56. https:\/\/doi.org\/10.1186\/1471-2407-8-56","journal-title":"BMC Cancer"},{"key":"8083_CR11","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1200\/jco.2010.32.5704","volume":"29","author":"B Gerber","year":"2011","unstructured":"Gerber B et al (2011) Effect of luteinizing hormone\u2013releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334\u20132341. https:\/\/doi.org\/10.1200\/jco.2010.32.5704","journal-title":"J Clin Oncol"},{"key":"8083_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s12032-013-0667-8","volume":"30","author":"G Song","year":"2013","unstructured":"Song G, Gao H, Yuan Z (2013) Effect of leuprolide acetate on ovarian function after cyclophosphamide\u2013doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 30:667. https:\/\/doi.org\/10.1007\/s12032-013-0667-8","journal-title":"Med Oncol"},{"key":"8083_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1634\/theoncologist.2013-0145","volume":"19","author":"NL Henry","year":"2014","unstructured":"Henry NL et al (2014) Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 19:68\u201374. https:\/\/doi.org\/10.1634\/theoncologist.2013-0145","journal-title":"Oncologist"},{"key":"8083_CR14","doi-asserted-by":"publisher","first-page":"e0140842","DOI":"10.1371\/journal.pone.0140842","volume":"10","author":"GS Liem","year":"2015","unstructured":"Liem GS et al (2015) Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PLoS ONE 10:e0140842. https:\/\/doi.org\/10.1371\/journal.pone.0140842","journal-title":"PLoS ONE"},{"key":"8083_CR15","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1093\/humrep\/dew224","volume":"31","author":"C Silva","year":"2016","unstructured":"Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC (2016) Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod 31:2737\u20132749. https:\/\/doi.org\/10.1093\/humrep\/dew224","journal-title":"Hum Reprod"},{"key":"8083_CR16","doi-asserted-by":"publisher","first-page":"114041","DOI":"10.1016\/j.ejogrb.2025.114041","volume":"311","author":"G Douganiotis","year":"2025","unstructured":"Douganiotis G, Markopoulou E, Vrana E, Kontovinis L, Papazisis K (2025) Assessment of parameters associated with ovarian function recovery in premenopausal women with early breast cancer and chemotherapy-induced amenorrhea in real-world clinical practice. Eur J Obstet Gynecol Reprod Biol 311:114041. https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114041","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"8083_CR17","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.3390\/curroncol30100666","volume":"30","author":"\u00c7 \u00dcnal","year":"2023","unstructured":"\u00dcnal \u00c7 et al (2023) Evaluation of anti-M\u00fcllerian hormone levels, antral follicle counts, and mean ovarian volumes in chemotherapy-induced amenorrhea among breast cancer patients: a prospective clinical study. Curr Oncol 30:9217\u20139229. https:\/\/doi.org\/10.3390\/curroncol30100666","journal-title":"Curr Oncol"},{"key":"8083_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12885-017-3593-x","volume":"17","author":"A Wenners","year":"2017","unstructured":"Wenners A et al (2017) Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. BMC Cancer 17:632. https:\/\/doi.org\/10.1186\/s12885-017-3593-x","journal-title":"BMC Cancer"},{"key":"8083_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1186\/s40064-016-2671-x","volume":"5","author":"XS Li","year":"2016","unstructured":"Li XS, Lv Q, Du ZG, Chen J (2016) Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical score. Springerplus 5:1052. https:\/\/doi.org\/10.1186\/s40064-016-2671-x","journal-title":"Springerplus"},{"key":"8083_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12885-025-14159-z","volume":"25","author":"C Raveendran","year":"2025","unstructured":"Raveendran C, Meloot SS, Yadev IP (2025) Clinical and biochemical amenorrhea in premenopausal patients with breast cancer treated with chemotherapy \u2013 a prospective cohort study. BMC Cancer 25:753. https:\/\/doi.org\/10.1186\/s12885-025-14159-z","journal-title":"BMC Cancer"},{"key":"8083_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"8083_CR22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"8083_CR23","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"8083_CR24","doi-asserted-by":"publisher","first-page":"104562","DOI":"10.1016\/j.breast.2025.104562","volume":"83","author":"C van Zwol-Janssens","year":"2025","unstructured":"van Zwol-Janssens C et al (2025) Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy. Breast 83:104562. https:\/\/doi.org\/10.1016\/j.breast.2025.104562","journal-title":"Breast"},{"key":"8083_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00404-012-2590-1","volume":"287","author":"N Ditsch","year":"2013","unstructured":"Ditsch N et al (2013) A retrospective investigation of women\u2019s experience with breast reconstruction after mastectomy. Arch Gynecol Obstet 287:555\u2013561. https:\/\/doi.org\/10.1007\/s00404-012-2590-1","journal-title":"Arch Gynecol Obstet"},{"key":"8083_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.14740\/wjon1991","volume":"16","author":"B Ng","year":"2025","unstructured":"Ng B, Ferintasari AD, Hutajulu SH, Astari YK, Wiranata JA, Suwardjo S, Widodo I, Choridah L, Dhamiyati W, Hardianti MS et al (2025) Patterns, predictors, and prognostic implication of treatment-related amenorrhea in patients with breast cancer. World J Oncol 16:200\u2013209. https:\/\/doi.org\/10.14740\/wjon1991","journal-title":"World J Oncol"},{"key":"8083_CR27","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.3390\/curroncol30100666","volume":"30","author":"\u00c7 \u00dcnal","year":"2023","unstructured":"\u00dcnal \u00c7, Ordu \u00c7, \u00d6zmen T, \u0130lgun AS, \u00c7elebi F, Baysal B, \u00d6zkurt E, Duymaz T, Erdo\u011fan \u0130yig\u00fcn Z, Kurt S et al (2023) Evaluation of anti-Mullerian hormone levels, antral follicle counts, and mean ovarian volumes in chemotherapy-induced amenorrhea among breast cancer patients: a prospective clinical study. Curr Oncol 30:9217\u20139229. https:\/\/doi.org\/10.3390\/curroncol30100666","journal-title":"Curr Oncol"},{"key":"8083_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamaoncol.2021.6214","volume":"8","author":"X Zong","year":"2022","unstructured":"Zong X, Yu Y, Yang H, Chen W, Ding X, Liu S, Li X, Chen X, Jiang C, Xia X et al (2022) Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial. JAMA Oncol 8:252\u2013258. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6214","journal-title":"JAMA Oncol"},{"key":"8083_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000514445","volume":"17","author":"R Torrisi","year":"2022","unstructured":"Torrisi R, Basilico V, Giordano L, Caruso M, Musolino A, Monari MN, Carnaghi C, Santoro A (2022) Is anti-M\u00fcllerian hormone a marker of ovarian reserve in young breast cancer patients receiving a GnRH analog during chemotherapy? Breast Care (Basel) 17:10\u201315. https:\/\/doi.org\/10.1159\/000514445","journal-title":"Breast Care (Basel)"},{"key":"8083_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-020-05951-5","volume":"186","author":"AK Turnbull","year":"2021","unstructured":"Turnbull AK, Patel S, Martinez-Perez C, Rigg A, Oikonomidou O (2021) Risk of chemotherapy-related amenorrhoea in premenopausal women undergoing chemotherapy for early stage breast cancer. Breast Cancer Res Treat 186:237\u2013245. https:\/\/doi.org\/10.1007\/s10549-020-05951-5","journal-title":"Breast Cancer Res Treat"},{"key":"8083_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3889\/oamjms.2021.6712","volume":"9","author":"M Mudib","year":"2021","unstructured":"Mudib M, Yarso KY, Nugroho HA (2021) Age as an independent factor in the permanent chemotherapy-induced amenorrhea incidence in breast cancer patients at Dr. Moewardi hospital, Surakarta, Indonesia. Open Access Maced J Med Sci 9:816\u2013820. https:\/\/doi.org\/10.3889\/oamjms.2021.6712","journal-title":"Open Access Maced J Med Sci"},{"key":"8083_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13058-024-01903-9","volume":"26","author":"YJ Lee","year":"2024","unstructured":"Lee YJ et al (2024) Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy. Breast Cancer Res 26:152. https:\/\/doi.org\/10.1186\/s13058-024-01903-9","journal-title":"Breast Cancer Res"},{"key":"8083_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.017","volume":"151","author":"HJ Kim","year":"2021","unstructured":"Kim HJ et al (2021) Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: an ASTRRA study report. Eur J Cancer 151:190\u2013200. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.017","journal-title":"Eur J Cancer"},{"key":"8083_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-020-05692-5","volume":"182","author":"T Iwamoto","year":"2020","unstructured":"Iwamoto T, Hara F, Uemura Y, Mukai H, Watanabe T, Ohashi Y (2020) NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy. Breast Cancer Res Treat 182:325\u2013332. https:\/\/doi.org\/10.1007\/s10549-020-05692-5","journal-title":"Breast Cancer Res Treat"},{"key":"8083_CR35","doi-asserted-by":"publisher","first-page":"e19566","DOI":"10.1097\/MD.0000000000019566","volume":"99","author":"HN Abdel-Razeq","year":"2020","unstructured":"Abdel-Razeq HN et al (2020) Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study. Med (Baltim) 99:e19566. https:\/\/doi.org\/10.1097\/MD.0000000000019566","journal-title":"Med (Baltim)"},{"key":"8083_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10549-018-4997-2","volume":"173","author":"C Xue","year":"2019","unstructured":"Xue C, Wei W, Sun P, Zheng W, Diao X, Xu F, Huang J, An X, Xia W, Hong R et al (2019) Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Res Treat 173:619\u2013628. https:\/\/doi.org\/10.1007\/s10549-018-4997-2","journal-title":"Breast Cancer Res Treat"},{"key":"8083_CR37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.4048\/jbc.2019.22.e53","volume":"22","author":"JJ Shin","year":"2019","unstructured":"Shin JJ, Choi YM, Jun JK, Lee KH, Kim TY, Han W, Im SA (2019) Amenorrhea and menopause in patients with breast cancer after chemotherapy. J Breast Cancer 22:624\u2013634. https:\/\/doi.org\/10.4048\/jbc.2019.22.e53","journal-title":"J Breast Cancer"},{"key":"8083_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clbc.2018.08.005","volume":"19","author":"B Pistilli","year":"2019","unstructured":"Pistilli B, Mazouni C, Zingarello A, Faron M, Saghatchian M, Grynberg M, Spielmann M, Kerbrat P, Roch\u00e9 H, Lorgis V et al (2019) Individualized prediction of menses recovery after chemotherapy for early-stage breast cancer: a nomogram developed from UNICANCER PACS04 and PACS05 trials. Clin Breast Cancer 19:63\u201370. https:\/\/doi.org\/10.1016\/j.clbc.2018.08.005","journal-title":"Clin Breast Cancer"},{"key":"8083_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10549-018-4660-y","volume":"168","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Ji Y, Li J, Lei L, Wu S, Zuo W, Jia X, Wang Y, Mo M, Zhang N et al (2018) Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: Effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat 168:679\u2013686. https:\/\/doi.org\/10.1007\/s10549-018-4660-y","journal-title":"Breast Cancer Res Treat"},{"key":"8083_CR40","doi-asserted-by":"publisher","first-page":"11372","DOI":"10.18632\/oncotarget.14532","volume":"8","author":"IJH Vriens","year":"2017","unstructured":"Vriens IJH, de Bie Dekker AJR, Aarts MJB, de Boer M, Van Hellemond IEG, Roijen JHE, van Golde RJT, Voogd AC, Tjan\u2013Heijnen VCG (2017) The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget 8:11372\u201311379. https:\/\/doi.org\/10.18632\/oncotarget.14532","journal-title":"Oncotarget"},{"key":"8083_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.breast.2017.07.007","volume":"35","author":"EK Trapp","year":"2017","unstructured":"Trapp EK, Steidl J, Rack B, Andergassen U, Jueckstock J, Kurt A, Vilsmaier T, Kupka MS, de Gregorio A, de Gregorio N et al (2017) Anti-M\u00fcllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy \u2013 a translational research project of the SUCCESS A study. Breast 35:130\u2013135. https:\/\/doi.org\/10.1016\/j.breast.2017.07.007","journal-title":"Breast"},{"key":"8083_CR42","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.fertnstert.2017.02.046","volume":"107","author":"N Sinha","year":"2017","unstructured":"Sinha N, Letourneau J, Kim J, Rosen M (2017) Higher antral follicle count associated with earlier return of ovarian function in breast cancer patients with temporary amenorrhea after chemotherapy. Fertil Steril 107:e26","journal-title":"Fertil Steril"},{"key":"8083_CR43","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12282-017-0764-1","volume":"24","author":"C Koga","year":"2017","unstructured":"Koga C, Akiyoshi S, Ishida M, Nakamura Y, Ohno S, Tokunaga E (2017) Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer 24:714\u2013719. https:\/\/doi.org\/10.1007\/s12282-017-0764-1","journal-title":"Breast Cancer"},{"key":"8083_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4048\/JBC.2017.20.1.91","volume":"20","author":"I Kim","year":"2017","unstructured":"Kim I, Ryu JM, Paik HJ, Park S, Bae SY, Lee SK, Yu JH, Kim SW, Nam SJ, Lee JE (2017) Fertility rates in young korean breast cancer patients treated with gonadotropin-releasing hormone and chemotherapy. J Breast Cancer 20:91\u201397. https:\/\/doi.org\/10.4048\/JBC.2017.20.1.91","journal-title":"J Breast Cancer"},{"key":"8083_CR45","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/jco.2015.62.2985","volume":"34","author":"LK Krekow","year":"2016","unstructured":"Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, Vukelja SJ, Holmes FA, Reddy PK, Asmar L et al (2016) Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol 34:1594\u20131600. https:\/\/doi.org\/10.1200\/jco.2015.62.2985","journal-title":"J Clin Oncol"},{"key":"8083_CR46","doi-asserted-by":"publisher","first-page":"e3301","DOI":"10.1097\/md.0000000000003301","volume":"95","author":"SJ Jeon","year":"2016","unstructured":"Jeon SJ, Lee JI, Jeon MJ, Lee M (2016) Prognostic effects of adjuvant chemotherapy-induced amenorrhea and subsequent resumption of menstruation for premenopausal breast cancer patients. Med (Baltim) 95:e3301. https:\/\/doi.org\/10.1097\/md.0000000000003301","journal-title":"Med (Baltim)"},{"key":"8083_CR47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1200\/jco.2011.34.6890","volume":"30","author":"PN Munster","year":"2012","unstructured":"Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE (2012) Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533\u2013538. https:\/\/doi.org\/10.1200\/jco.2011.34.6890","journal-title":"J Clin Oncol"},{"key":"8083_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1001\/jama.2011.991","volume":"306","author":"L Del Mastro","year":"2011","unstructured":"Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:269\u2013276. https:\/\/doi.org\/10.1001\/jama.2011.991","journal-title":"JAMA"},{"key":"8083_CR49","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.fertnstert.2013.03.014","volume":"99","author":"RA Anderson","year":"2013","unstructured":"Anderson RA, Wallace WHB (2013) Antim\u00fcllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 99:1469\u20131475. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.03.014","journal-title":"Fertil Steril"},{"key":"8083_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2009.12.005","volume":"76","author":"F Tomao","year":"2010","unstructured":"Tomao F, Spinelli GP, Panici PB, Frati L, Tomao S (2010) Ovarian function, reproduction and strategies for fertility preservation after breast cancer. Crit Rev Oncol Hematol 76:1\u201312. https:\/\/doi.org\/10.1016\/j.critrevonc.2009.12.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"8083_CR51","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/jco.2013.52.8877","volume":"32","author":"KJ Ruddy","year":"2014","unstructured":"Ruddy KJ et al (2014) Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 32:1151\u20131156. https:\/\/doi.org\/10.1200\/jco.2013.52.8877","journal-title":"J Clin Oncol"},{"key":"8083_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.fertnstert.2009.03.045","volume":"94","author":"AH Partridge","year":"2010","unstructured":"Partridge AH et al (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94:638\u2013644. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.03.045","journal-title":"Fertil Steril"},{"key":"8083_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2016.10.034","volume":"71","author":"M Lambertini","year":"2017","unstructured":"Lambertini M et al (2017) Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer 71:25\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.034","journal-title":"Eur J Cancer"},{"key":"8083_CR54","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HC Moore","year":"2015","unstructured":"Moore HC et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923\u2013932. https:\/\/doi.org\/10.1056\/NEJMoa1413204","journal-title":"N Engl J Med"},{"key":"8083_CR55","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.7150\/jca.31859","volume":"10","author":"Y Zhong","year":"2019","unstructured":"Zhong Y et al (2019) GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer. J Cancer 10:4278\u20134285. https:\/\/doi.org\/10.7150\/jca.31859","journal-title":"J Cancer"},{"key":"8083_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","volume":"87","author":"RA Anderson","year":"2017","unstructured":"Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF (2017) The utility of anti-M\u00fcllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 87:58\u201364. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.001","journal-title":"Eur J Cancer"},{"key":"8083_CR57","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/jco.22.01065","volume":"41","author":"PA Francis","year":"2023","unstructured":"Francis PA et al (2023) Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol 41:1370\u20131375. https:\/\/doi.org\/10.1200\/jco.22.01065","journal-title":"J Clin Oncol"},{"key":"8083_CR58","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1200\/jco-24-02782","volume":"43","author":"HI Su","year":"2025","unstructured":"Su HI et al (2025) Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol 43:1488\u20131515. https:\/\/doi.org\/10.1200\/jco-24-02782","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08083-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:08:43Z","timestamp":1790107723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08083-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8083"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08083-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics, consent to participate, and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"20"}}